An observational study showed Moderna is associated with increased effectiveness vs. Pfizer vaccine against symptomatic SARS-CoV-2 infection.
13 Dec, 2021 | 09:52h | UTCComparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection – Med
Related:
Opinion | Is Moderna really better than Pfizer—or is it just a higher dose?
Commentary on Twitter
New @MedCellPress
Comparative effectiveness of the Pfizer and Moderna vaccines over time, in both the Alpha and Delta US waves, vs symptomatic infections https://t.co/RlWUXeZ2f2
consistent 8-12 % points advantage for Moderna pic.twitter.com/IwHXFIKaEp— Eric Topol (@EricTopol) December 11, 2021